

This material is an English translation of the press release announced on August 25, 2015 in Japanese, and the Japanese release is given priority about the content and the interpretation.

August 25, 2015

**Notice concerning the decision of matters relating to acquisition of company's own shares.
(Acquisition of company's own shares under the regulations of the articles of association
in accordance to paragraph 2, article 165 of the corporation law)**

Hisamitsu Pharmaceutical Co., Inc. (Head office: Tosu city, Saga Prefecture, Japan: Chairman and CEO: Hiroataka Nakatomi, hereinafter referred to as Hisamitsu) hereby notices that it resolved matters relating to acquisition of company's own shares as follows under the regulations of Article 156 of the Corporations Laws as being changed to read and applied upon the regulations of Paragraph 3, Article 165 of the Corporation Law at the Meeting of the Board of Directors held today.

1. Reason to acquire company's own shares.

To improve capital efficiency and to attempt more distribution of profit to shareholders, and to perform mobile capital policy corresponding to the change of managerial environment.

2. Content of matters concerning acquisition.

(1) Class of targeted shares to acquire: Common shares of Hisamitsu.

(2) Total number of shares acquirable: One million shares (ceiling).

(Ratio to total number of issued shares[excluding company's own shares] 1.17%)

(3) Total amount of acquired value of share: 4,500 million Yen (ceiling).

(4) Period for acquisition: From September 1, 2015 to February 29, 2016.

Reference: Condition of company's own shares held as of May 31, 2015.

▪ Total number of issued shares (excluding company's own shares) 85,694,147 shares.

▪ Number of company's own shares 9,470,748 shares.